WallStSmart

Ciena Corp (CIEN)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 5% more annual revenue ($5.40B vs $5.12B). RMD leads profitability with a 27.5% profit margin vs 4.5%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).

CIEN

Buy

54

out of 100

Grade: C-

Growth: 6.7Profit: 5.5Value: 4.7Quality: 7.5
Piotroski: 6/9Altman Z: 1.18

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CIENSignificantly Overvalued (-299.5%)

Margin of Safety

-299.5%

Fair Value

$74.41

Current Price

$437.70

$363.29 premium

UndervaluedFair: $74.41Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CIEN2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

Market CapQuality
$60.74B9/10

Large-cap with strong market position

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

CIEN4 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

EPS GrowthGrowth
2.3%4/10

2.3% earnings growth

Profit MarginProfitability
4.5%3/10

4.5% margin — thin

P/E RatioValuation
270.1x2/10

Premium valuation, high expectations priced in

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : CIEN

The strongest argument for CIEN centers on Revenue Growth, Market Cap. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : CIEN

The primary concerns for CIEN are PEG Ratio, EPS Growth, Profit Margin. A P/E of 270.1x leaves little room for execution misses. Thin 4.5% margins leave little buffer for downturns.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

CIEN profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.

CIEN carries more volatility with a beta of 1.09 — expect wider price swings.

CIEN is growing revenue faster at 33.1% — sustainability is the question.

RMD generates stronger free cash flow (311M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (70/100 vs 54/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ciena Corp

TECHNOLOGY · COMMUNICATION EQUIPMENT · USA

Ciena Corporation provides hardware, software, and network services that support the transport, routing, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks worldwide. The company is headquartered in Hanover, Maryland.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?